Please assess the completion status of the following clinical trial:

Trial Title: Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and above.~* Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.~* History of AD for ≥1 year.~* Subjects who have a recent history of inadequate response to treatment with topical medications.~* AD involvement of ≥10% body surface area at screening and baseline.~* Stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation.~Exclusion Criteria:~* Subjects for whom TCS are medically inadvisable e.g., due to important side effects or safety risks in the opinion of the investigator.~* Active dermatologic conditions that may confound the diagnosis of AD.~* Use of tanning beds or phototherapy within 6 weeks prior to randomisation.~* Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to randomisation.~* Treatment with TCS, topical calcineurin inhibitors (TCI), or topical phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomisation.~* Receipt of any marketed biological therapy (i.e. immunoglobulin, anti- immunoglobulin E) including dupilumab or investigational biologic agents within 3 months or 5 half-lives, whichever is longer prior to randomisation.~* Active skin infection within 1 week prior to randomisation.~* Clinically significant infection within 4 weeks prior to randomisation.~* A helminth parasitic infection within 6 months prior to the date informed consent is obtained.~* Tuberculosis requiring treatment within the 12 months prior to screening.~* Known primary immunodeficiency disorder.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tralokinumab(initial)responders-> Tralokinumab(continuation A) (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A.
- Tralokinumab(initial)responders-> Tralokinumab(continuation B) (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen B.
- Tralokinumab(initial)non-respon-> Tralokinumab(continuation A) (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Tralokinumab loading SC injection on Day 0 followed by tralokinumab injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A.
- Placebo (initial)non-respon-> Tralokinumab(continuation A) (Type: EXPERIMENTAL): Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Tralokinumab continuation SC injection regimen A.
- Placebo(initial)responders-> Placebo(continuation A) (Type: PLACEBO_COMPARATOR): Week 0 to 16 (initial period):~Placebo loading SC injection on Day 0 followed by placebo injection regimen A.~Week 16 to 32 (continuation period):~Placebo continuation SC injection regimen A.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete